View source for Maribavir

{{Drugbox
| IUPAC_name        = (2''S'',3''S'',4''R'',5''S'')-2-[5,6-Dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol
| image             = Maribavir.png
| CAS_number        = 176161-24-3
| ATC_prefix        = J05
| ATC_suffix        = AX10
| PubChem           = 471161
| DrugBank          = 
| C=15| H=19| C=l2| N=3| O=4
| molecular_weight  = 376.24 g/mol
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      =  <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU =  <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA =  <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK =  <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US =  <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
}}

'''Maribavir''' is an experimental [[Route of administration|oral]] [[antiviral drug]] candidate licensed by [[ViroPharma]] from [[GlaxoSmithKline]] in 2003 for the [[Prophylaxis|prevention]] and treatment of human [[cytomegalovirus]] disease in [[hematopoietic stem cell]]/[[bone marrow transplant]] patients.  It showed promise in [[clinical trial#Phase II|Phase II]] clinical trials and was granted [[FDA Fast Track Development Program|fast track]] status, but failed to meet study goals in a Phase III trial.

A Phase II study with maribavir demonstrated that [[prophylaxis]] with maribavir displayed strong antiviral activity, as measured by [[statistically significant]] reduction in the rate of reactivation of CMV in recipients of [[hematopoietic stem cell]]/[[bone marrow transplant]]s.<ref>[http://www.medicalnewstoday.com/articles/109557.php Phase 2 Data Shows Maribavir Markedly Reduced Rate Of Cytomegalovirus Infection And Disease In Bone Marrow Transplant Patients], ''Medical News Today'', Jun 2, 2008</ref> In an [[intent-to-treat]] analysis of the first 100 days after the transplant, the number of subjects who required pre-emptive anti-CMV therapy was statistically significantly reduced with maribavir compared to placebo.

ViroPharma conducted a [[clinical trial#Phase III|Phase III]] clinical study to evaluate the [[Prophylaxis|prophylactic]] use for the prevention of cytomegalovirus disease in recipients of [[tissue engineering|allogeneic]] [[stem cell]] transplant patients.  In February 2009, ViroPharma announced that the Phase III study failed to achieve its goal, showing no significant difference between maribavir and a placebo in reducing the rate of CMV disease.<ref>[http://money.cnn.com/news/newsfeeds/articles/djf500/200902091012DOWJONESDJONLINE000320_FORTUNE5.htm ViroPharma:Maribavir Phase III Study Missed Goal;Shares Plunge], CNN Money, February 09, 2009</ref>

==References==
{{reflist}}

{{DNA antivirals}}

[[Category:Antivirals]]
[[Category:Benzimidazoles]]
[[Category:Nucleosides]]
[[Category:Organochlorides]]


{{antiinfective-drug-stub}}
[[Category:2Fix]]